{
    "clinical_study": {
        "@rank": "67092", 
        "acronym": "BOX-AF", 
        "arm_group": {
            "arm_group_label": "Rivaroxaban"
        }, 
        "brief_summary": {
            "textblock": "The objective of this NIS is to assess in a real-life setting, usage patterns and associated\n      outcomes in the management (healthcare resource utilisation and associated costs) of\n      patients with non-valvular AF treated with Xarelto, in accordance with the terms of the\n      European marketing authorization and the Belgian reimbursement criteria."
        }, 
        "brief_title": "Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients \u2265 18 years old with a confirmed diagnosis of non-valvular atrial\n             fibrillation\n\n          -  Patients must in addition present with at least one of following risk factors:\n\n               -  prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous\n                  system) systemic embolism\n\n               -  left ventricular ejection fraction of < 40%\n\n               -  symptomatic heart failure, New York Heart Association class 2 or higher\n\n               -  age \u226575 years\n\n               -  age \u226565 years in combination with either diabetes, coronary disease or arterial\n                  hypertension\n\n        Exclusion Criteria:\n\n          -  Patients who do not fulfil the Belgian reimbursement criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Ambulatory or hospitalized patients coming from the cardiology clinic of the participating\n        hospitals"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855139", 
            "org_study_id": "16851", 
            "secondary_id": "XA1313BE"
        }, 
        "intervention": {
            "arm_group_label": "Rivaroxaban", 
            "description": "15 mg OD or 20 mg OD", 
            "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-valvular atrial fibrillation", 
            "Stroke", 
            "Systemic embolism", 
            "Oral anticoagulation", 
            "Real-life setting", 
            "Preventive measure"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many locations", 
                    "country": "Belgium"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Belgian Real Life Non-interventional Study (NIS) on Xarelto\u00ae in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Real-life medical resource use consumption based on medical examination and patient diary cards", 
            "safety_issue": "No", 
            "time_frame": "Up to 1.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855139"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}